Dapagliflozin — Drug Intelligence | 65 EU Trials

Filter these 65 trials by condition, phase, country and more.

Open in Search →

65 Registered trials

28 Recruiting

28 Completed trials

49 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 25 Phase II/III: 2 Phase II: 15 Phase I/II: 1 Phase III/IV: 1 Phase IV: 20 Other: 1

Oversight events:

3 serious breaches 1 urgent safety measure 2 corrective measures across 5 trials

View oversight register →

Indications tested

Chronic kidney disease 7 Type 2 diabetes mellitus 3 IgA nephropathy 3 Hypertension 3 Acute myocardial infarction 2 Cardiac failure 2 Heritable pulmonary arterial hypertension 1 Obesity 1 Glomerulonephritis membranous 1 Laboratory test abnormal 1 Pulmonary arterial hypertension 1 Cardiac amyloidosis 1

Sponsors using this IMP

AstraZeneca AB 9 Eli Lilly & Co. 3 Novo Nordisk A/S 3 Odense University Hospital 3 Assistance Publique Hopitaux De Paris 2 Centre Hospitalier Universitaire De Nantes 2 Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA 2 Oslo University Hospital HF 2 Region Midtjylland 2 Universitaetsmedizin Goettingen 2 4 Wojskowy Szpital Kliniczny Z Polikliniką Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu 1 Aarhus University Hospital 1

All trials

65 total

ASPIRE-1: dApagliflozin SC0062 and Prevention of renal Injury; a Randomized Evaluation Not authorised

2023-504404-28-00 Phase II 3 countries University Medical Center Groningen
Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab – a randomized head to head study Not authorised

2025-523714-92-00 Phase II 1 country Centrum Medyczne Ksztalcenia Podyplomowego
Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure Pending

2024-513799-16-00 Phase IV 1 country Ziekenhuis Oost Limburg
A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Phase III 1 country Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali
SGLT2 lnhibition in Hemodialysis (DAPA-HD) Pending

2024-518591-31-00 Phase II 1 country Medical University Of Vienna
The SGL-TX-PTDM study Pending

2024-518774-14-00 Phase II 1 country Odense University Hospital
Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction Pending

2025-520969-51-00 Phase IV 1 country Fundación para la Innovación en Biomedicina; Fundacion Para La Investigacion Bio…
Early use of dapagliflozin in patients with acute myocardial infarction and reduced ejection fraction: the randomized ARMYDA-9 Dapagliflozin… Pending

2025-521481-10-00 Phase IV 1 country Azienda Ospedaliero-Universitaria Maggiore Della Carita
Sodium-glucose cotransporter-2 inhibitors to stabilize coronary ather-osclerosis progression after acute myocardial infarction in women and … Pending

2025-523375-29-00 Phase III 1 country Humanitas Mirasole S.p.A.
Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting

2025-520660-18-00 Phase IV 1 country Policlinico San Donato S.p.A.
STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting

2025-521276-59-00 Phase III 4 countries University Of Cologne
SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION Recruiting

2025-520794-39-00 Phase III 6 countries Universitaetsklinikum Schleswig-Holstein AöR
Impact of dapagliflozin for the regulation of immunological activity in Membranous Nephropathy Recruiting

2023-507658-34-00 Phase II/III 1 country Centre Hospitalier Universitaire De Nice
A Phase IIb study to evaluate the effect of combination of dapagliflozin and baxdrostat compared with baxdrostat alone in participants with … Recruiting

2025-522407-23-00 Phase II 2 countries AstraZeneca AB
The REVERT-PREDIABETES trial Recruiting

2025-522970-35-00 Phase III/IV 1 country Region Midtjylland
Dapagliflozine for cardio-renal protection at ICU discharge Recruiting

2024-510941-32-00 Phase III 1 country Assistance Publique Hopitaux De Paris
SGLT-2i, Heart, Improvement of Cardiovascular Autonomic Neuropathy Recruiting

2025-521748-39-00 Phase IV 1 country Universita Cattolica Del Sacro Cuore
Urinary proteomics to guide early intervention to prevent complications in type 2 diabetes – a feasibility study Recruiting

2024-518682-95-00 Phase IV 2 countries Steno Diabetes Center Copenhagen
SGL-TX-GFR SGLT2i safety and efficacy on kidney allograft function in non-diabetic kidney transplant recipients: A randomized, double-blind,… Recruiting

2024-518773-33-00 Phase IV 1 country Odense University Hospital
Dapagliflozin in the treatment of decompensated liver cirrhosis: phase IIb randomised, controlled clinical trial Recruiting

2024-511964-95-00 Phase II 1 country Azienda Ospedale-Universita Padova
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with co… Recruiting

2023-508525-27-00 Phase IV 1 country Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut …
Searching simple biomarkers to phenotype type 2 diabetic patients and personalize their treatment Recruiting

2024-516542-19-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu… Recruiting

2023-506460-14-00 Phase III 15 countries Astrazeneca AB
STunning in Acute Myocardial Infarction – Beta blockers, Angiotensin converting enzyme inhibitors and Sodium/glucose cotransporter 2 inhibit… Recruiting

2024-511789-35-00 Phase IV 1 country University Of Gothenburg; Vaestra Goetalandsregionen

Showing 1–24 of 65 trials

← All drugs A–Z